NASDAQ:CDXC - Chromadex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.00 -0.12 (-2.92 %)
(As of 04/23/2019 08:43 AM ET)
Previous Close$4.12
Today's Range$3.96 - $4.10
52-Week Range$2.79 - $5.00
Volume123,036 shs
Average Volume185,412 shs
Market Capitalization$220.87 million
P/E RatioN/A
Dividend YieldN/A
Beta1.12
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and finished products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California.

Receive CDXC News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDXC
CUSIPN/A
Phone310-388-6706

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.56 million
Book Value$0.49 per share

Profitability

Net Income$-33,320,000.00
Net Margins-105.57%

Miscellaneous

Employees100
Market Cap$220.87 million
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable

Chromadex (NASDAQ:CDXC) Frequently Asked Questions

What is Chromadex's stock symbol?

Chromadex trades on the NASDAQ under the ticker symbol "CDXC."

How were Chromadex's earnings last quarter?

Chromadex Corp (NASDAQ:CDXC) announced its quarterly earnings results on Thursday, March, 7th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01. The company earned $9.07 million during the quarter, compared to the consensus estimate of $9.21 million. Chromadex had a negative net margin of 105.57% and a negative return on equity of 90.20%. View Chromadex's Earnings History.

When is Chromadex's next earnings date?

Chromadex is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Chromadex.

What price target have analysts set for CDXC?

2 equities research analysts have issued 12 month price objectives for Chromadex's shares. Their forecasts range from $7.00 to $7.00. On average, they expect Chromadex's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 75.2% from the stock's current price. View Analyst Price Targets for Chromadex.

What is the consensus analysts' recommendation for Chromadex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chromadex.

Has Chromadex been receiving favorable news coverage?

News articles about CDXC stock have been trending somewhat negative on Tuesday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chromadex earned a news impact score of -1.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future.

Who are some of Chromadex's key competitors?

What other stocks do shareholders of Chromadex own?

Who are Chromadex's key executives?

Chromadex's management team includes the folowing people:
  • Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 51)
  • Mr. Robert N. Fried, CEO & Director (Age 59)
  • Mr. Kevin M. Farr, Chief Financial Officer (Age 61)
  • Mr. Ben Shichman, Chief Technology Officer
  • Dr. Matthew Roberts, Chief Scientific Officer & Sr. VP of Innovation

How do I buy shares of Chromadex?

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chromadex's stock price today?

One share of CDXC stock can currently be purchased for approximately $3.9950.

How big of a company is Chromadex?

Chromadex has a market capitalization of $220.87 million and generates $31.56 million in revenue each year. The company earns $-33,320,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Chromadex employs 100 workers across the globe.

What is Chromadex's official website?

The official website for Chromadex is http://www.chromadex.com.

How can I contact Chromadex?

Chromadex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at [email protected]


MarketBeat Community Rating for Chromadex (NASDAQ CDXC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  353 (Vote Outperform)
Underperform Votes:  369 (Vote Underperform)
Total Votes:  722
MarketBeat's community ratings are surveys of what our community members think about Chromadex and other stocks. Vote "Outperform" if you believe CDXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel